TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31998994

Group type: EXPERIMENTAL
Intervention: Count-only approaches
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Negative control counts
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Standard estimators based on CRTs with negative controls
Number of subjects: 0
Study: 30558972

Group type: EXPERIMENTAL
Intervention: Minimally invasive surgery (MIS) with laparoscopic interval debulking surgery (IDS); 51 patients underwent laparoscopic IDS, 25 had laparoscopic optimal cytoreduction (76% R0).
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: Surgical complexity score (SCS) ≥ 3; in multivariate analyses, SCS ≥ 3 was significantly predictive of worse disease-specific overall survival (DSS) (p = 0.04).
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: Age 75+; in multivariate analyses, age 75+ was significantly predictive of worse DSS (p ≤ 0.001).
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: Residual disease >1 cm; in multivariate analyses, residual disease >1 cm was significantly predictive of worse DSS (p = 0.03).
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: Optimal debulking defined as R0; in the R0 cohort, SCS did not significantly predict DSS.
Number of subjects: 282
Study: 29944894

Group type: EXPERIMENTAL
Intervention: Distributed training with real-time feedback
Number of subjects: 87

Group type: COMPARATOR
Intervention: Conventional BLS training (control)
Number of subjects: 87
Study: 27347999

Group type: EXPERIMENTAL
Intervention: Iso HMS
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Low HMS
Number of subjects: 10

Group type: COMPARATOR
Intervention: G
Number of subjects: 10
Study: 24192642

Group type: EXPERIMENTAL
Intervention: Caffeine (3 mg/kg)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 22118999

Group type: EXPERIMENTAL
Intervention: 1% tropicamide eye drops
Number of subjects: 471

Group type: EXPERIMENTAL
Intervention: Oral acetazolamide
Number of subjects: 471
Study: 20388753

Group type: EXPERIMENTAL
Intervention: High-intensity NPPV (mean inspiratory pressure of 28.6+/−1.9 mbar)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: High-intensity NPPV
Number of subjects: 17

Group type: COMPARATOR
Intervention: Low-intensity NPPV (mean inspiratory pressure of 14.6+/−0.8 mbar)
Number of subjects: 17
Study: 17486918

Group type: EXPERIMENTAL
Intervention: Single bolus of neuromuscular blocking drug (rocuronium) at induction
Number of subjects: 0

Group type: COMPARATOR
Intervention: Continuous infusion of neuromuscular blocking drugs
Number of subjects: 0
Study: 15606435

Group type: EXPERIMENTAL
Intervention: Lornoxicam (8 mg single oral dose)
Number of subjects: 18

Group type: COMPARATOR
Intervention: CYP2C9 polymorphism
Number of subjects: 18
Study: 12199005

Group type: EXPERIMENTAL
Intervention: Mandibular advancement splint (MAS)
Number of subjects: 19
Study: 9988249

Group type: EXPERIMENTAL
Intervention: Nutramigen
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Enfamil
Number of subjects: 60

Group type: COMPARATOR
Intervention: Human milk
Number of subjects: 60
Study: 7777246

Group type: EXPERIMENTAL
Intervention: Ondansetron administered in group A: 8 mg IV infusion over 10 min before CDDP, followed by 8 mg orally every 8 h for 3 days.
Number of subjects: 80

Group type: COMPARATOR
Intervention: Ondansetron administered in group B: six intravenous doses every 6 h starting 12.5 h before cisplatin, followed by 8 mg orally every 6 h for 3 days.
Number of subjects: 80
Study: 2225876

Group type: EXPERIMENTAL
Intervention: 25 mg urapidil infusion
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 7074752

Group type: EXPERIMENTAL
Intervention: Incremental exercise program
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 42
Study: 30734126

Group type: EXPERIMENTAL
Intervention: Organic fraction group
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Mineral water group
Number of subjects: 74

Group type: COMPARATOR
Intervention: Tap water group
Number of subjects: 74
Study: 29980770

Group type: EXPERIMENTAL
Intervention: Single-piece IOL
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Three-piece IOL
Number of subjects: 0

Group type: COMPARATOR
Intervention: Single-piece IOL and Three-piece IOL
Number of subjects: 0
Study: 27397118

Group type: EXPERIMENTAL
Intervention: Ultrasound technique (out‐of‐plane orientation and in‐plane guidance)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Palpation technique (control)
Number of subjects: 88
Study: 24977721

Group type: EXPERIMENTAL
Intervention: Internet-based safety decision aid
Number of subjects: 59
Study: 22090454

Group type: EXPERIMENTAL
Intervention: Supervised interaction with real patients
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Role playing
Number of subjects: 140

Group type: COMPARATOR
Intervention: Lecture
Number of subjects: 140

Group type: COMPARATOR
Intervention: Web-based training
Number of subjects: 140
Study: 21090333

Group type: EXPERIMENTAL
Intervention: Moxibustion plus electroacupuncture (M + EA)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Medication (Antine Capsule, diclofenac sodium, 50 mg, twice daily)
Number of subjects: 124
Study: 19192762

Group type: EXPERIMENTAL
Intervention: 50 mg of tramadol in 3‐mL saline
Number of subjects: 8

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 8
Study: 15903126

Group type: EXPERIMENTAL
Intervention: Ximelagatran (24, 36, 48, or 60 mg twice daily for 12 to 16 days)
Number of subjects: 264
Study: 12628948

Group type: EXPERIMENTAL
Intervention: Baseline BNP above median
Number of subjects: 4300

Group type: EXPERIMENTAL
Intervention: Baseline NE above median
Number of subjects: 4300

Group type: EXPERIMENTAL
Intervention: BNP quartiles
Number of subjects: 4300

Group type: EXPERIMENTAL
Intervention: Percent decrease in BNP from baseline to 4 and 12 months
Number of subjects: 4300

Group type: EXPERIMENTAL
Intervention: Percent increase in BNP from baseline to 4 and 12 months
Number of subjects: 4300

Group type: EXPERIMENTAL
Intervention: Percent decrease in NE from baseline to 4 and 12 months
Number of subjects: 4300

Group type: EXPERIMENTAL
Intervention: Percent increase in NE from baseline to 4 and 12 months
Number of subjects: 4300
Study: 10346073

Group type: EXPERIMENTAL
Intervention: Sequential assignment (SA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 0
Study: 7851581

Group type: EXPERIMENTAL
Intervention: Buserelin acetate for 3 months (n = 20)
Number of subjects: 30

Group type: COMPARATOR
Intervention: No treatment (n = 10)
Number of subjects: 30
Study: 1659239

Group type: EXPERIMENTAL
Intervention: Pentamidine isethionate intravenously three times each week until parasitological cure
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: Pentamidine concomitantly with a 20-day regimen of sodium stibogluconate
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: Pentamidine injections followed by 20 days of sodium stibogluconate therapy
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: Pentamidine (5 additional injections) followed by a course of antimony therapy
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: Pentamidine
Number of subjects: 312
Study: 6797298

Group type: EXPERIMENTAL
Intervention: Cimetidine 400 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Cimetidine 200 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Cimetidine 200 mg + Oxyphenonium bromide 10 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 31842950

Group type: EXPERIMENTAL
Intervention: Tetramethylpyrazine (TMP) 100 mg orally three times a day for 16 weeks
Number of subjects: 120

Group type: COMPARATOR
Intervention: Routine treatment (Control)
Number of subjects: 120
Study: 29216898

Group type: EXPERIMENTAL
Intervention: Neuromuscular exercise
Number of subjects: 100

Group type: COMPARATOR
Intervention: Quadriceps strengthening exercise
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Knee flexor strength
Number of subjects: 100
Study: 26175552

Group type: EXPERIMENTAL
Intervention: Bowel preparation (BP)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Non-bowel preparation (NP)
Number of subjects: 78
Study: 24345167

Group type: EXPERIMENTAL
Intervention: Developmental dyscalculia
Number of subjects: 0

Group type: COMPARATOR
Intervention: Numerically normal adults
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gray matter volume in right TPJ
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Number proficiency
Number of subjects: 0
Study: 22863310

Group type: EXPERIMENTAL
Intervention: Dialysis patients with diabetes
Number of subjects: 301

Group type: COMPARATOR
Intervention: Diabetes in dialysis patients
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Mental aspects of HRQOL in diabetic patients receiving dialysis
Number of subjects: 301
Study: 19574177

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 44

Group type: COMPARATOR
Intervention: No acupuncture (control)
Number of subjects: 44
Study: 17539711

Group type: EXPERIMENTAL
Intervention: Scaling and root planing plus chlorhexidine chips
Number of subjects: 26

Group type: COMPARATOR
Intervention: Scaling and root planing alone
Number of subjects: 26
Study: 15096808

Group type: EXPERIMENTAL
Intervention: Breastfeeding
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not breastfeeding (Control)
Number of subjects: 0
Study: 11479153

Group type: COMPARATOR
Intervention: Biliary atresia
Number of subjects: 86

Group type: COMPARATOR
Intervention: Fulminant hepatitis
Number of subjects: 86

Group type: COMPARATOR
Intervention: Neonatal hepatitis
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Plasma HGF levels
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Plasma TGF-beta1 levels
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Plasma HGF-TGF-beta1 ratio
Number of subjects: 86
Study: 9504599

Group type: EXPERIMENTAL
Intervention: Melatonin 3.0 mg nightly for 30 days
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo nightly for 30 days
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Melatonin for patients with bilateral tinnitus
Number of subjects: 30
Study: 7527674

Group type: EXPERIMENTAL
Intervention: Unmanipulated marrow transplant from HLA-identical siblings
Number of subjects: 58
Study: 2646872

Group type: EXPERIMENTAL
Intervention: Gd-DTPA (0.1 mmol/kg)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 88
Study: 1239216

Group type: EXPERIMENTAL
Intervention: Bupivacaine and saline solution
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Bupivacaine and LMW dextran 40
Number of subjects: 18

Group type: COMPARATOR
Intervention: Saline and LMW dextran 40
Number of subjects: 18
Study: 31188080

Group type: EXPERIMENTAL
Intervention: High fruit and vegetable intake (≥ 4.9 servings/day)
Number of subjects: 1026

Group type: EXPERIMENTAL
Intervention: Highest quartile of fruit intake
Number of subjects: 1026

Group type: EXPERIMENTAL
Intervention: Highest quartile of vegetable intake
Number of subjects: 1026

Group type: COMPARATOR
Intervention: Dairy products intake
Number of subjects: 1026
Study: 28358546

Group type: EXPERIMENTAL
Intervention: Performance feedback intervention
Number of subjects: 228
Study: 25753873

Group type: EXPERIMENTAL
Intervention: Nasal Duo positive airway pressure (DuoPAP)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Nasal continuous positive airway pressure (nCPAP)
Number of subjects: 85
Study: 23492965

Group type: EXPERIMENTAL
Intervention: VeinViewer
Number of subjects: 600

Group type: COMPARATOR
Intervention: Routine cannulation
Number of subjects: 600
Study: 21639660

Group type: EXPERIMENTAL
Intervention: Video-tape role induction (RI)
Number of subjects: 68

Group type: COMPARATOR
Intervention: No videotape treatment-as-usual
Number of subjects: 68
Study: 18048452

Group type: EXPERIMENTAL
Intervention: Phentolamine (alpha-adrenoceptor inhibition)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Combined phentolamine/propranolol (alpha- and beta-adrenoceptor inhibition)
Number of subjects: 14
Study: 15644460

Group type: EXPERIMENTAL
Intervention: Moderate-intensity leg extension exercise (6 sets of 8 repetitions at 80% of 1-RM)
Number of subjects: 12
Study: 12876237

Group type: EXPERIMENTAL
Intervention: Entacapone 200 mg with each daily levodopa dose
Number of subjects: 300

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study: 10378705

Group type: EXPERIMENTAL
Intervention: Education group (4-week education program, 2 hours per week)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Education group
Number of subjects: 77

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 77
Study: 8712328

Group type: EXPERIMENTAL
Intervention: Combination of 0.0625% bupivacaine with either 2.5 micrograms.ml‐1 fentanyl or 0.25 micrograms.ml‐1 sufentanil
Number of subjects: 399

Group type: COMPARATOR
Intervention: 0.125% plain bupivacaine
Number of subjects: 399
Study: 1521397

Group type: EXPERIMENTAL
Intervention: Electronic toothbrush
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo toothbrush (conventional toothbrush)
Number of subjects: 26
Study: 6387717

Group type: EXPERIMENTAL
Intervention: Diflunisal
Number of subjects: 19

Group type: COMPARATOR
Intervention: Naproxen
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Diflunisal and Naproxen
Number of subjects: 19
Study: 30821716

Group type: EXPERIMENTAL
Intervention: Sustained nicorandil administration (5 mg, three times daily)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Single nicorandil administration before PCI (control group)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Sustained nicorandil administration
Number of subjects: 117
Study: 29712593

Group type: EXPERIMENTAL
Intervention: Laparoscopic Heller myotomy with partial fundoplication
Number of subjects: 0

Group type: COMPARATOR
Intervention: Laparoscopic Heller myotomy with partial anterior fundoplication
Number of subjects: 0

Group type: COMPARATOR
Intervention: Laparoscopic Heller myotomy with partial posterior fundoplication
Number of subjects: 0
Study: 27037483

Group type: EXPERIMENTAL
Intervention: Habit Reversal Training (HRT) group sessions
Number of subjects: 33

Group type: COMPARATOR
Intervention: Education group sessions
Number of subjects: 33
Study: 23435555

Group type: EXPERIMENTAL
Intervention: Self-incentivizing implementation intention condition
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: Standard implementation intention condition
Number of subjects: 238

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 238
Study: 21864866

Group type: EXPERIMENTAL
Intervention: HTG clamp
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: HTG/IG clamp
Number of subjects: 10

Group type: COMPARATOR
Intervention: Insulin and glucose administration
Number of subjects: 10
Study: 20550712

Group type: EXPERIMENTAL
Intervention: 60 minutes of moderate-intensity aerobic and resistance training, five days per week for 24 weeks
Number of subjects: 80

Group type: COMPARATOR
Intervention: 45 minutes of stretching, five days per week for 24 weeks
Number of subjects: 80
Study: 18094378

Group type: EXPERIMENTAL
Intervention: Telbivudine 600 mg once daily
Number of subjects: 1370

Group type: COMPARATOR
Intervention: Lamivudine 100 mg once daily
Number of subjects: 1370
Study: 14579089

Group type: EXPERIMENTAL
Intervention: 360 degrees data collection
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 180 degrees data collection
Number of subjects: 30
Study: 10960219

Group type: EXPERIMENTAL
Intervention: Acts of violence perpetration (self-reported)
Number of subjects: 349

Group type: EXPERIMENTAL
Intervention: Victimization and witnessing of violent events
Number of subjects: 349

Group type: EXPERIMENTAL
Intervention: Individual risk behaviors and victimization
Number of subjects: 349

Group type: EXPERIMENTAL
Intervention: Acts of perpetration
Number of subjects: 349
Study: 9108976

Group type: EXPERIMENTAL
Intervention: Worn Polymacon lenses (unwashed)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Washed worn lenses of both types
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unworn lenses (controls)
Number of subjects: 0
Study: 8264339

Group type: EXPERIMENTAL
Intervention: Fish oil (n-3 PUFA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 3915155

Group type: EXPERIMENTAL
Intervention: Single dose 250 mg mefloquine
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Single dose 500 mg mefloquine
Number of subjects: 46

Group type: COMPARATOR
Intervention: Standard 3-day treatment with 1,500 mg chloroquine
Number of subjects: 46
Study: 30865324

Group type: EXPERIMENTAL
Intervention: Strong Hearts, Healthy Communities (SHHC) intervention; met 1 hour twice a week for 24 weeks, involving aerobic exercise and progressive strength training.
Number of subjects: 192

Group type: COMPARATOR
Intervention: Control program; met 1 hour each month for 6 months, covering dietary and physical activity recommendations.
Number of subjects: 192
Study: 29337405

Group type: EXPERIMENTAL
Intervention: Active TENS
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo TENS
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control
Number of subjects: 84
Study: 27116510

Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab injections
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Haplotype analysis of rs699947, rs2010963, and rs3025039 SNPs
Number of subjects: 90
Study: 24255160

Group type: COMPARATOR
Intervention: Visual estimation of height
Number of subjects: 100

Group type: COMPARATOR
Intervention: Tape measure height measurement
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Lower leg measurements
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Forearm measurements
Number of subjects: 100

Group type: COMPARATOR
Intervention: Reference method (height gauge while standing)
Number of subjects: 100
Study: 22933669

Group type: EXPERIMENTAL
Intervention: Gender-specific NexGen LPS High-Flex prosthesis
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard NexGen LPS prosthesis
Number of subjects: 100
Study: 20929110

Group type: EXPERIMENTAL
Intervention: HTK solution (nonflushed)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: HTK solution (flushed)
Number of subjects: 89

Group type: COMPARATOR
Intervention: University of Wisconsin (UW) solution
Number of subjects: 89
Study: 18418230

Group type: EXPERIMENTAL
Intervention: High-fat meal (group 1, n=40)
Number of subjects: 60

Group type: COMPARATOR
Intervention: High-fat meal (group 3, n=20)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (group 2, n=20, no high-fat meal)
Number of subjects: 60
Study: 15661405

Group type: EXPERIMENTAL
Intervention: Purging with 25 mug/mL ET‐18‐OCH3 combined with cryopreservation at 10% DMSO and hyperthermia at 42 degrees C combined with cryopreservation at 10% or 4% DMSO
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Minimal residual disease (MRD) levels
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: MRD levels categorized
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Log tumor reduction needed to achieve MRD cut-off of 0.05%
Number of subjects: 54
Study: 12232643

Group type: EXPERIMENTAL
Intervention: 0.01 mg/kg cisatracurium (Cis 6 group: pretreatment interval 6 min)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 0.01 mg/kg cisatracurium (Cis 3 group: pretreatment interval 3 min)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Normal saline i.v. (Placebo group)
Number of subjects: 60
Study: 10705622

Group type: EXPERIMENTAL
Intervention: Short-term hormone replacement therapy (< 10 months)
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Long-term hormone replacement therapy (> 11 months)
Number of subjects: 216

Group type: COMPARATOR
Intervention: Control group (nonusers)
Number of subjects: 216
Study: 8758316

Group type: EXPERIMENTAL
Intervention: 1 MAC enflurane
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 1 MAC isoflurane
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (thiopental and 67% N2O‐O2)
Number of subjects: 18
Study: 1746257

Group type: EXPERIMENTAL
Intervention: 20 ml normal saline solution
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: 30 ml normal saline solution
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: 40 ml normal saline solution
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Oxytocin 10 units in 20 ml saline solution
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Oxytocin 10 units in 40 ml saline solution
Number of subjects: 125
Study: 7064040

Group type: EXPERIMENTAL
Intervention: Topical application of lignocaine
Number of subjects: 41
Study: 31367893

Group type: EXPERIMENTAL
Intervention: Physical Therapy + Balneotherapy (PT + BT)
Number of subjects: 305

Group type: COMPARATOR
Intervention: Physical Therapy alone (PT)
Number of subjects: 305
Study: 28805022

Group type: EXPERIMENTAL
Intervention: Hesperidin 500 mg/day for 6 weeks
Number of subjects: 64
Study: 25528759

Group type: EXPERIMENTAL
Intervention: Going outside into a busy local shopping street
Number of subjects: 59

Group type: COMPARATOR
Intervention: Staying inside (neutral task indoors)
Number of subjects: 59
Study: 25622744

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine preconditioning (Pre-Dex group) - intravenous infusion at a dose of 0.125 ml/kg (4 µg/ml) for 10 minutes before tourniquet use.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (R group) - conventional general anesthesia, received normal saline equivalent to dexmedetomidine volume.
Number of subjects: 60
Study: 22269229

Group type: EXPERIMENTAL
Intervention: Fluoride varnish (Cavity Shield) applied three times during one week (once every 2 days)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Control group (no fluoride varnish)
Number of subjects: 250
Study: 19542421

Group type: EXPERIMENTAL
Intervention: Flared-end stents
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Bent-end stents
Number of subjects: 122
Study: 17474806

Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg
Number of subjects: 668

Group type: EXPERIMENTAL
Intervention: Duloxetine 120 mg
Number of subjects: 668

Group type: EXPERIMENTAL
Intervention: Duloxetine 60-120 mg (flexible dose)
Number of subjects: 668

Group type: EXPERIMENTAL
Intervention: Duloxetine treatment
Number of subjects: 668

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 668
Study: 15526245

Group type: EXPERIMENTAL
Intervention: Statin therapy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 11502951

Group type: EXPERIMENTAL
Intervention: Quality Improvement (QI) interventions
Number of subjects: 46

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 46